CALIXAR EXTENDS PATENT PROTECTION TO ITS NATIVE ISOLATION PLATFORM FOR COMPLEX THERAPEUTIC TARGETS AND ANTIGENS IN JAPAN
Lyon, France, 12 May 2015 – CALIXAR, the French biotech company specialized in the functional and native isolation of complex therapeutic targets and antigens, announces the grant of the patent related to its unique platform for selectively extracting membrane proteins. After its grant in Europe and in USA, this new patent allows the company to extend and strengthen its global presence in the field of target isolation for drug discovery and antigen isolation for new vaccines (JP 5592879).
Emmanuel DEJEAN, CEO of CALIXAR declared: “Asia and in particular Japan is a major player in the pharmaceutical market and this grant is a great step forward for our company in this area for human and animal health as well as for crop science”.
